Trial Evaluating 3-year Disease Free Survival in Patients With Locally Advanced Rectal Cancer Treated With Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative Management
Rectal Cancer CAPECITABINE (ORAL) FLUOROURACIL LEUCOVORIN OXALIPLATIN Total mesorectal excision Chemoradiation therapy Total neoadjuvant therapy 13-213 Rectal Neoplasms Capecitabine Oxaliplatin (OXAL) 5-Fluorouracil (5-FU) Capecitabine (Xeloda®) intensity modulated radiotherapy (IMRT) DRE-Endoscopy INCT CNCT
Lead Scientist at UCSF
- Madhulika Varma
Dr. Madhulika Varma, Chief of Colorectal Surgery, specializes in the surgical treatment of diseases of the colon, rectum, and anus. Her areas of expertise include colon and rectal cancer, inflammatory bowel diseases such as ulcerative colitis, Crohn’s disease, and pelvic floor disorders.